Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Jan;23(1):67-9.
doi: 10.4103/0970-1591.30271.

Treatment algorithm in hormone-resistant prostate cancer: Practical guidelines

Makarand V Khochikar  1
Affiliations

Treatment algorithm in hormone-resistant prostate cancer: Practical guidelines

Makarand V Khochikar. Indian J Urol. 2007 Jan.

Abstract

Treatment of hormone-resistant prostate cancer can be a challenging situation. The first important step in treating this condition is to assess if one has achieved the castrate level or not. If the castrate levels are not achieved, attempt should be made to achieve so. If the castrate level is achieved, then androgen withdrawals may be of help. Supportive care, care of the clinical problems forms an integral part of the treatment. Cancer-specific chemotherapy is certainly an option in progressive disease.

Keywords: Cancer-specific chemotherapy; castrate levels; hormone-resistant prostate cancer; psycho-oncology; secondary hormonal therapy; supportive care.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

References

    1. Jeffrey M Kamradt, Kenneth J Pienta. New Paradigms in the Management of Hormone Refractory Disease. In: Klein EA, editor. Management of prostate cancer. Totowa, New Jersey: Humana Press; 2000.
    1. Hussain M, Wolf M, Marshall E, Crawford ED, Eisenberger M. Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: A Southwest Oncology Group report. J Clin Oncol. 1994;12:1868–75. - PubMed
    1. Taylor CD, Elson P, Trump DL. Importance of continued testicular suppression in hormone-refractory prostate cancer. J Clin Oncol. 1993;11:2167–72. - PubMed
    1. Kelly WK, Scher HI. Prostate specific antigen decline after antiandrogen withdrawal: The Flutamide withdrawal syndrome. J Urol. 1993;149:607–9. - PubMed
    1. Scher HI, Kelley WK. Flutamide withdrawal syndrome: Its impact on clinical trials in hormone refractory prostate cancer. J Clin Oncol. 1993;11:1566–72. - PubMed